STAT3 and melanoma: Similar to the RAS/BRAF/MAPK signaling activation, down-regulation of STAT3 by lentiviral shRNA in STAT3-activated melanoma resulted in inhibition of multiple immunosuppressive cytokines, including IL-6, IL-10, and VEGF, indicating that STAT3 inhibitors may also be useful for immunotherapy (Sumimoto et al., 2006).